From quantum dots to nano-droplets: Commercializing life science tools & diagnostics
Inventions in leading academic labs can appear to have the potential to transform many areas of bio-analysis. This talk will discuss real-world successes and pitfalls in the quest to commercialize radically new and different approaches to bio-analysis using nanotechnology-inspired approaches. Product development, venture financing, market development, and case studies will be presented.
Andy Watson, is the Vice President of Corporate Development at Cell Signaling Technology (CST), where he is responsible for managing the companion diagnostic portfolio, mergers and acquisitions, and strategy. In his previous position as Chief Commercial Officer at RainDance Technologies, Andy led the company’s global marketing and strategy efforts in commercial targeted sequencing and prepared the market for the launch of digital PCR and single cell analysis products. Andy has more than 20 years of experience in developing and commercializing innovative genomics technologies. He is the inventor on more than 25 issued patents and applications and is the author of 10 scientific publications. Andy holds M.Eng, M.A., and B.A. degrees from King’s College, Cambridge University.